Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fluid Energy Conversion (FEC), a subsidiary of Vystar Corporation, specializes in proprietary fluidic and boundary layer technologies designed to manipulate the flow of liquids and gases. The company's core asset is the patented Hughes Reactor, which harnesses sound energy and controlled cavitation to enhance chemical reactions and destroy pathogens without the use of moving parts. In the healthcare sector, FEC's technology is integrated into RxAir UV-C air purification systems to maximize the destruction of airborne bacteria and viruses in clinical and residential settings. Additionally, FEC is developing advanced water filtration systems for dialysis machines to improve efficiency and reduce waste, as well as precision dosage control solutions for vaporized drug delivery devices. Led by medical professionals including nephrologist Dr. Bryan Stone, the company bridges the gap between mechanical engineering and life sciences to provide sustainable healthcare solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fluid Energy Conversion.